Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database

Prabhakar Mithal, Lauren E. Howard, William J. Aronson, Christopher J. Kane, Matthew R. Cooperberg, Martha Kennedy Terris, Christopher L. Amling, Stephen J. Freedland

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To assess the ability of preoperative prostate-specific antigen level, Gleason score and stage to predict prostate cancer outcomes beyond biochemical recurrence, specifically castration-resistant prostate cancer, metastases and prostate cancer-specific mortality in radical prostatectomy patients. Methods: We carried out a retrospective study of 2735 men in the Shared Equal Access Regional Cancer Hospital database treated by radical prostatectomy from 1988 to 2011 with data available on pathological stage, grade and preoperative prostate-specific antigen. We used Cox hazards analyses to examine the predictive accuracy (c-index) of the preoperative prostate-specific antigen (log-transformed), path Gleason score (≤7, 3+4, 4+3 and 8-10) and path stage grouping (pT2 negative margins; pT2 positive margins; pT3a negative margins; pT3a positive margins; pT3b; vs positive nodes) to predict biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality. Results: Median follow up was 8.7years, during which, 937 (34%) had biochemical recurrence, 108 (4%) castration-resistant prostate cancer, 127 (5%) metastases and 68 (2%) prostate cancer-specific mortality. For the outcomes of biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality, the c-indices were, respectively: prostate-specific antigen 0.65, 0.66, 0.64 and 0.69; Gleason score 0.66, 0.83, 0.76 and 0.85; and pathological stage group 0.69, 0.76, 0.72 and 0.80. Conclusions: Gleason score can predict with very high accuracy prostate cancer-specific mortality in patients undergoing radical prostatectomy. Thus, Gleason score should be given more weight in nomograms to predict prostate cancer-specific mortality. Furthermore, men with a high Gleason score should be given special consideration for adjuvant treatment or referral to clinical trials because of a higher risk of prostate cancer-specific mortality.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
JournalInternational Journal of Urology
Volume22
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Cancer Care Facilities
Neoplasm Grading
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Databases
Castration
Mortality
Neoplasm Metastasis
Recurrence
Nomograms

Keywords

  • Disease progression
  • Mortality
  • Prostatectomy
  • Prostatic neoplasms
  • Risk factors

ASJC Scopus subject areas

  • Urology

Cite this

Prostate-specific antigen level, stage or Gleason score : Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. / Mithal, Prabhakar; Howard, Lauren E.; Aronson, William J.; Kane, Christopher J.; Cooperberg, Matthew R.; Terris, Martha Kennedy; Amling, Christopher L.; Freedland, Stephen J.

In: International Journal of Urology, Vol. 22, No. 4, 01.04.2015, p. 362-366.

Research output: Contribution to journalArticle

Mithal, Prabhakar ; Howard, Lauren E. ; Aronson, William J. ; Kane, Christopher J. ; Cooperberg, Matthew R. ; Terris, Martha Kennedy ; Amling, Christopher L. ; Freedland, Stephen J. / Prostate-specific antigen level, stage or Gleason score : Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. In: International Journal of Urology. 2015 ; Vol. 22, No. 4. pp. 362-366.
@article{d4d47aeeb48549aeb886fa0c5e9b2692,
title = "Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database",
abstract = "Objectives: To assess the ability of preoperative prostate-specific antigen level, Gleason score and stage to predict prostate cancer outcomes beyond biochemical recurrence, specifically castration-resistant prostate cancer, metastases and prostate cancer-specific mortality in radical prostatectomy patients. Methods: We carried out a retrospective study of 2735 men in the Shared Equal Access Regional Cancer Hospital database treated by radical prostatectomy from 1988 to 2011 with data available on pathological stage, grade and preoperative prostate-specific antigen. We used Cox hazards analyses to examine the predictive accuracy (c-index) of the preoperative prostate-specific antigen (log-transformed), path Gleason score (≤7, 3+4, 4+3 and 8-10) and path stage grouping (pT2 negative margins; pT2 positive margins; pT3a negative margins; pT3a positive margins; pT3b; vs positive nodes) to predict biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality. Results: Median follow up was 8.7years, during which, 937 (34{\%}) had biochemical recurrence, 108 (4{\%}) castration-resistant prostate cancer, 127 (5{\%}) metastases and 68 (2{\%}) prostate cancer-specific mortality. For the outcomes of biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality, the c-indices were, respectively: prostate-specific antigen 0.65, 0.66, 0.64 and 0.69; Gleason score 0.66, 0.83, 0.76 and 0.85; and pathological stage group 0.69, 0.76, 0.72 and 0.80. Conclusions: Gleason score can predict with very high accuracy prostate cancer-specific mortality in patients undergoing radical prostatectomy. Thus, Gleason score should be given more weight in nomograms to predict prostate cancer-specific mortality. Furthermore, men with a high Gleason score should be given special consideration for adjuvant treatment or referral to clinical trials because of a higher risk of prostate cancer-specific mortality.",
keywords = "Disease progression, Mortality, Prostatectomy, Prostatic neoplasms, Risk factors",
author = "Prabhakar Mithal and Howard, {Lauren E.} and Aronson, {William J.} and Kane, {Christopher J.} and Cooperberg, {Matthew R.} and Terris, {Martha Kennedy} and Amling, {Christopher L.} and Freedland, {Stephen J.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/iju.12704",
language = "English (US)",
volume = "22",
pages = "362--366",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Prostate-specific antigen level, stage or Gleason score

T2 - Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database

AU - Mithal, Prabhakar

AU - Howard, Lauren E.

AU - Aronson, William J.

AU - Kane, Christopher J.

AU - Cooperberg, Matthew R.

AU - Terris, Martha Kennedy

AU - Amling, Christopher L.

AU - Freedland, Stephen J.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objectives: To assess the ability of preoperative prostate-specific antigen level, Gleason score and stage to predict prostate cancer outcomes beyond biochemical recurrence, specifically castration-resistant prostate cancer, metastases and prostate cancer-specific mortality in radical prostatectomy patients. Methods: We carried out a retrospective study of 2735 men in the Shared Equal Access Regional Cancer Hospital database treated by radical prostatectomy from 1988 to 2011 with data available on pathological stage, grade and preoperative prostate-specific antigen. We used Cox hazards analyses to examine the predictive accuracy (c-index) of the preoperative prostate-specific antigen (log-transformed), path Gleason score (≤7, 3+4, 4+3 and 8-10) and path stage grouping (pT2 negative margins; pT2 positive margins; pT3a negative margins; pT3a positive margins; pT3b; vs positive nodes) to predict biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality. Results: Median follow up was 8.7years, during which, 937 (34%) had biochemical recurrence, 108 (4%) castration-resistant prostate cancer, 127 (5%) metastases and 68 (2%) prostate cancer-specific mortality. For the outcomes of biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality, the c-indices were, respectively: prostate-specific antigen 0.65, 0.66, 0.64 and 0.69; Gleason score 0.66, 0.83, 0.76 and 0.85; and pathological stage group 0.69, 0.76, 0.72 and 0.80. Conclusions: Gleason score can predict with very high accuracy prostate cancer-specific mortality in patients undergoing radical prostatectomy. Thus, Gleason score should be given more weight in nomograms to predict prostate cancer-specific mortality. Furthermore, men with a high Gleason score should be given special consideration for adjuvant treatment or referral to clinical trials because of a higher risk of prostate cancer-specific mortality.

AB - Objectives: To assess the ability of preoperative prostate-specific antigen level, Gleason score and stage to predict prostate cancer outcomes beyond biochemical recurrence, specifically castration-resistant prostate cancer, metastases and prostate cancer-specific mortality in radical prostatectomy patients. Methods: We carried out a retrospective study of 2735 men in the Shared Equal Access Regional Cancer Hospital database treated by radical prostatectomy from 1988 to 2011 with data available on pathological stage, grade and preoperative prostate-specific antigen. We used Cox hazards analyses to examine the predictive accuracy (c-index) of the preoperative prostate-specific antigen (log-transformed), path Gleason score (≤7, 3+4, 4+3 and 8-10) and path stage grouping (pT2 negative margins; pT2 positive margins; pT3a negative margins; pT3a positive margins; pT3b; vs positive nodes) to predict biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality. Results: Median follow up was 8.7years, during which, 937 (34%) had biochemical recurrence, 108 (4%) castration-resistant prostate cancer, 127 (5%) metastases and 68 (2%) prostate cancer-specific mortality. For the outcomes of biochemical recurrence, castration-resistant prostate cancer, metastases and prostate cancer-specific mortality, the c-indices were, respectively: prostate-specific antigen 0.65, 0.66, 0.64 and 0.69; Gleason score 0.66, 0.83, 0.76 and 0.85; and pathological stage group 0.69, 0.76, 0.72 and 0.80. Conclusions: Gleason score can predict with very high accuracy prostate cancer-specific mortality in patients undergoing radical prostatectomy. Thus, Gleason score should be given more weight in nomograms to predict prostate cancer-specific mortality. Furthermore, men with a high Gleason score should be given special consideration for adjuvant treatment or referral to clinical trials because of a higher risk of prostate cancer-specific mortality.

KW - Disease progression

KW - Mortality

KW - Prostatectomy

KW - Prostatic neoplasms

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84925946704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925946704&partnerID=8YFLogxK

U2 - 10.1111/iju.12704

DO - 10.1111/iju.12704

M3 - Article

C2 - 25728968

AN - SCOPUS:84925946704

VL - 22

SP - 362

EP - 366

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 4

ER -